This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Adam's Most Recent Article

MannKind's Afrezza Lags Behind Biggest Failure in Inhaled Insulin

06/30/15 - 11:27 AM EDT

The number of prescriptions written for MannKind's inhaled insulin drug Afrezza are barely making a dent in the diabetes market five months after partner Sanofi launched the product.

read more >

Other Articles by Adam

Free Reports

Receptos Insider Sale Defies Logic if Takeout Is Imminent

06/17/15 - 11:05 AM EDT

Lilly Ventures, the venture capital arm of the pharmaceutical giant with a seat on Receptos' board, just sold a good chunk of the company's stock.

read more >
Avalanche Fails Common-Sense Test, Kicked Out of Gene Therapy Credibility Club

06/16/15 - 06:53 AM EDT

I wanted to slam my forehead against the desk after the Avalanche CEO repeated for the 600th time, 'The key takeaway today is that it's a positive study.'

read more >
Agios Blood Cancer Drugs Are Fine -- It's the Analysis That's Causing Confusion

06/15/15 - 12:03 PM EDT

Agios shares are falling because investors thought the performance of its cancer drugs fell short, but only the method used to calculate response changed.

read more >
Bluebird Sickle Cell Gene Therapy Results Keep Getting Better

06/13/15 - 05:32 AM EDT

Six months after infusion with the Bluebird gene therapy known as LentiGlobin, almost half of the oxygen-carrying red blood cells in a single patient are normal and functioning.

read more >
Agios 'Cancer Metabolism' Drugs Induce Prolonged Responses in Blood Cancer Patients

06/12/15 - 05:55 AM EDT

Updated results from two early-stage studies of Agios' AG-221 and AG-110 are being presented at a European medical meeting.

read more >
Advisory Panel Recommends Bluebird Delay Gene Therapy Clinical Trial

06/09/15 - 08:18 PM EDT

The company's CEO said that Bluebird's plans had not changed despite a government panel's recommendation to delay the start of the trial until more data is gathered.

read more >
Diabetes Docs Wary of MannKind's Afrezza Insulin, Analyst Survey Finds

06/09/15 - 09:08 AM EDT

Jefferies analyst gives excellent lesson in how to spin something positive from a negative MannKind survey when investment banking calls.

read more >
Inside the Hedge Fund Club Pitching a New Alzheimer's Drug IPO

06/08/15 - 02:34 PM EDT

The Axovant Sciences IPO, scheduled for this week, is one of those clubby hedge-fund deals which explains why most investors believe Wall Street is an unfair game.

read more >
Titan Pharma Opioid Addiction Implant Passes Key Study Hurdle

06/08/15 - 07:01 AM EDT

Titan and its partner will resubmit Probuphine for FDA approval later this year.

read more >
Biotech Stock Mailbag: More Duchenne Drama, CAR-T Trouble, ASCO '15 Rewind

06/05/15 - 05:02 AM EDT

Biotech columnist Adam Feuerstein answers readers' questions about health care.

read more >
Page 2 of 337
Top Rated Stocks Top Rated Funds Top Rated ETFs